Population pharmacokinetics of recombinant factor VIII:C (ReFacto®) in adult HIV-negative and HIV-positive haemophilia patients

European Journal of Clinical Pharmacology

Volumn 65, Issue 11, 2009, Pages 1121-1130

  Karafoulidou, Anastasia ^a   Suarez, Elena ^b   Anastasopoulou, Ioanna ^a   Katsarou, Olga ^a   Kouramba, Anna ^a   Kotsi, Paraskevi ^a   Zografidis, Anastasios ^b   Lukas, John C ^c,d  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Dynakin Ltd   (France)

^d Dynakin Ltd   (Spain)

Author keywords

Factor VIII; Haemophilia; HIV positive; Monte Carlo simulation proportions; Population Pharmacokinetics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; BOOTSTRAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MONTE CARLO METHOD; POPULATION DYNAMICS; PRIORITY JOURNAL; SIMULATION;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; FACTOR VIII; HEMOPHILIA A; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 70350216170     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0699-3     Document Type: Article

References (20)

1. JM Lusher CA Lee CM Kessler CL Bedrosian 2003 The safety and efficacy of B-domain deleted recombinant factor VIII concentration in patients with severe haemophilia A Haemophilia 9 38 49 10.1046/j.1365-2516.2003.00708.x 1:CAS:528:DC%2BD3sXhslWgtL0%3D 12558777
2. A Gringeri A Tagliaferri G Tagariello M Morfini E Santagostino P Mannucci The AICE Study Group 2004 Efficacy and inhibitor development in previously treated patients with haemophilia A switched to B domain-deleted recombinant factor VIII Br J Hematol 126 398 404 10.1111/j.1365-2141.2004.05058.x 1:CAS:528:DC%2BD2cXntVyht7w%3D (Pubitemid 39022569)
3. European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products. Core SPC for human plasma derived and recombinant coagulation factor VIII products. (CPMP/BPWG/1619/99) [online]. Available from URL: http://www.emea.europa.eu/-pdfs/human/bpwg/161999en.pdf [Accessed 2009 Feb 13]
4. M Lee M Morfini C Negrier V Chamouard 2006 The pharmacokinetics of coagulation factors Haemophilia 12 Suppl 3 1 7 1:CAS:528:DC%2BD28XovFyltLY%3D 16683990
5. T Tencer HS Friedman J Li-McLeod K Johnson 2007 Medical costs and resource utilization for haemophilia patients with and without HIV or HIC infection JMCP 13 790 798 18062730
6. A Giraldini N Schinaia F Chiarotti R De Biasi F Rodeghiero N Binkin 1994 Epidemiology of haemophilia and HIV infection in Italy. GICC: Gruppo Italiano Coagulopatie Congenite J Clin Epidemiol 47 1297 1306 10.1016/0895-4356(94)90135- X (Pubitemid 24361538)
7. S Björkman E Berntorp 2001 Pharmacokinetics of coagulation factors: Clinical relevance for patients with haemophilia Clin Pharmacokinet 40 815 832 10.2165/00003088-200140110-00003 11735604
8. T Barrowcliffe E Berntorp V Blanchette S Björkman M Carcao D DiMichele, et al. 2006 State of the art international symposium on pharmacokinetics of factor concentrates in haemophilia: challenges and relevance to clinical practice. Summary statement Haemophilia 12 Suppl.4 3 5
9. AD Shapiro J korth-Bradley MC Poon 2005 Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia Haemophilia 11 571 582 10.1111/j.1365-2516.2005.01149.x 1:CAS:528:DC%2BD2MXht1GhsbzF 16236106 (Pubitemid 41631591)
10. M Lee M Morfini C Negrier V Chamouard 2006 The pharmacokinetics of coagulation factors Haemophilia 12 Suppl 3 1 7 1:CAS:528:DC%2BD28XovFyltLY%3D 16683990
11. M Morfini 2003 Pharmacokinetics of factor VIII and factor IX Haemophilia 9 Suppl 1 94 100 10.1046/j.1365-2516.9.s1.8.x 1:CAS:528:DC%2BD3sXks1agtrc%3D 12709044
12. J Ahnström E Berntorp K Lindvall S Björkman 2004 A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia Haemophilia 10 689 697 10.1111/j.1365-2516.2004.01036.x 15569163 (Pubitemid 40028584)
13. DR Mungall TM Ludden J Marshall DW Hawkins RL Talbert MH Crawford 1985 Population pharmacokinetics of racemic warfarin in adult patients J Pharmacokinet Biopharm 13 213 227 10.1007/BF01065653 1:STN:280: DyaL287hsVyhtw%3D%3D 3841364 (Pubitemid 16194622)
14. M Bolon-Larger V Chamouard F Bressolle R Boulieu 2007 A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with haemophilia A Ther Drug Monit 28 20 26 10.1097/FTD.0b013e3180311384 (Pubitemid 46279872)
15. M Mikaelson U Oswaldsson MA Jankowski 2001 Measurement of factor VIII activity of B-domain deleted recombinant factor VIII Semin Hematol 38 Suppl. 4 13 23 10.1016/S0037-1963(01)90104-0 (Pubitemid 32618680)
16. Beal SL, Sheiner LB, (eds) (1992) NONMEM user's guides. San Francisco (CA): NONMEM Project Group, University of California at San Francisco
17. Guidance for Industry: Population pharmacokinetics. Http:// www.fda.gov/ CDER/guidance/1852fnl.pdf. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologic Evaluation and Research ( CBER), February 1999.
18. S Bjorkman 2003 Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective Haemophilia 9 101 110 10.1046/j.1365-2516. 9.s1.4.x 1:CAS:528:DC%2BD3sXks1agt74%3D 12709045
19. JT Wilde 2004 HIV and HCV coinfection in haemophilia Haemophilia 10 1 8 10.1046/j.1351-8216.2003.00828.x 1:STN:280:DC%2BD2c%2FntlOltQ%3D%3D 14962214 (Pubitemid 40045393)
20. KG Donati R Rabagliati L Lacoviello R Cauda 2004 HIV infection, HAART, and endothelial adhesion molecules: current prespectives Lancet Infect Dis 4 213 222 10.1016/S1473-3099(04)00971-5 (Pubitemid 38407303)